Company: KROS
Filing Date: 2025-11-20
Form Type: SC TO-I/A
Source: 0001104659-25-114608
Chunk: 0

Company: Keros Therapeutics, Inc.
Filing Date: 2025-11-20
Form: SC TO-I/A
Chunk 0
---
<div align='center'>SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

Amendment No. 2 to

SCHEDULE TO

TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1)
OF THE SECURITIES EXCHANGE ACT OF 1934

Keros Therapeutics, Inc.

(Name of Subject Company (Issuer))

Keros Therapeutics, Inc.

(Names of Filing Persons (Issuer and Offeror))

Common Stock, $0.0001 par value per share

(Title of Class of Securities)

492327101

(CUSIP Number of Class of Securities)

Jasbir Seehra
Chief Executive Officer
Keros Therapeutics, Inc.
1050 Waltham Street, Suite 302
Lexington, Massachusetts 02421
Tel: (617) 314-6297

(Name, Address and Telephone Number of Person Authorized
to
Receive Notices and Communications on Behalf of Filing Persons)

With copies to:</div>

| Marc A. Recht               
 Ryan S. Sansom              
 Kevin Cooper                
 William Roegge              
 Cooley LLP                  
 500 Boylston Street         
 Boston, Massachusetts 02116 
 (617) 937-2300              |     | Esther Cho                     
 General Counsel                
 Keros Therapeutics, Inc.       
 1050 Waltham Street, Suite 302 
 Lexington, Massachusetts 02421 
 (617) 314-6297                 |     | Gregory P. Rodgers          
 Nathan Ajiashvili           
 Latham & Watkins LLP        
 1271 Avenue of the Americas 
 New York, New York 10020    
 (212) 906-1200              |

| ¨ | Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer. |

Check the appropriate boxes below to designate any transactions to
which the statement relates:

| ¨ | third-party tender offer subject to Rule 14d-1. |
| x | issuer                                          
 tender offer subject to Rule 13e-4.             |
| ¨ | going-private                                   
 transaction subject to Rule 13e-3.              |
| ¨ | amendment                                       
 to Schedule 13D under Rule 13d-2.               |

Check the following box if the filing is a final amendment reporting the results of the tender offer: ¨

If applicable, check the appropriate box(es) below to designate the
appropriate rule